Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Latest News
Big patent losses expected this year
Generic Competition: This year will see a number of important drugs come off patent, including two biologicals that could add fuel to the biosimilar prescribing debate.
MSD starts Brenzys events for HCPs
Launch Preparations: Sydney-based event aimed at rheumatologists and other HCPs presages PBS listing for controversial etanercept biosimilar but a launch date remains unclear.
J&J is top pharma says big business
Reputation: A Fortune Magazine survey of top business types has placed J&J 13th, well ahead of other big pharmas.
Roche sends TGA new cancer drug
Pipeline: Roche has filed its latest lung cancer drug Alecensa in Australia, seeking approval as a treatment following disease progression on Pfizer's Xalkori.
Trump should bone up on drug pricing: Bayer boss
Pricing: Bayer's global CEO Werner Baumann has said Donald Trump's understanding of why drugs cost what they cost could do with some improvement.
Most Popular
TGA boss predicts more uncertainty
Regulatory Change: The TGA's John Skerritt has predicted that uncertainty for industry and regulators will be an increasing feature of future regulation.
Pfizer case to curb generic marketing
Generics: Pfizer's win against Apotex in the Federal Court last week is likely to restrict the marketing activities of generic producers in the lead up to patent expiry, according to prominent IP lawyers.
Doctors rely heavily on MSLs & reps
Information Sources: A study of Australian specialists finds that medical and sales reps are primary source of drug information alongside colleagues and publications such as NPS Radar.
Merger rumours swirl round BMS
Companies: Analyst speculation is rampant that Bristol-Myers Squibb is a prime candidate for a mega-merger or acquisition and that Roche, Novartis and Pfizer...and even Gilead...may be circling.
Lyrica rivals free to seek PBS listing
Generics: Generic versions of Pfizer's Lyrica could reach the PBS as early as August with the Federal Court making way for generics makers to apply for listing before the patent expires.
Pfizer Adelaide's loss is Croatia's gain
Manufacturing: A report in Croatian state media says the production from Pfizer's Adelaide plant will move to Zagreb when Pfizer Australia exits the site in 2021.
Teva will look to PBS list cannabis
Medicines Access: Teva will be involved in the interim cannabis importation scheme announced by Health Minister Greg Hunt - but the ultimate aim is clinical trials and eventual PBS listing, says MD John Michailidis.
Nurofen class action picks up pace
Consumer Strikeback: A class action against Reckitt Benckiser over its Nurofen Specific Pain Range looks set to move to the next level with litigation funding and indemnity insurance in place, and the hunt on for an extra lead applicant.
Icahn targets BMS, stoking merger talk
Companies: Notable activist investor purchases a stake in BMS, sending its stock shooting upwards and fuelling speculation that the US$90 billion company is ripe for a takeover.
EBOS reports strong first half
Wholesalers: Pharmacy wholesaler EBOS has reported a strong first half for 2016/17 but massive sales of new hep C drugs disguised on-going challenges.
Pipeline Monitor
Celgene scores with old and new drugs
Celgene's Revlimid has won an additional indication in the US while the company's potential blockbuster, ozanimod, has enjoyed success in a head-to-had trial against Biogen's Avonex.
Debating Point
Expert games not very convincing
Both sides in the battle over the future of biosimilar prescribing in Australia have been rolling out their foreign experts but it's hard to see how fly-in, fly-out expertise can influence a government facing multiple budget management problems at home.
Approvals Action
New delivery for Cimzia
UCB registers new pen form of bDMARD Cimzia while competitors for Pfizer Lyrica continue to grow.
Debating Point
Mixed messages on state of Aussie pharma
Australian pharma industry leaders who responded to our annual survey of business conditions for 2016 have said they were the best in half a decade but does this signal real improvement or just a bottoming out after a succession of really bad years?
FREE Content
Events & Conferences
Pharma in Focus Jobs